| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7431944 | SANDOZ | Delivery of multiple doses of medications |
Dec, 2015
(8 years ago) | |
| US5908850 | SANDOZ | Method of treating attention deficit disorders with d-threo methylphenidate |
Dec, 2015
(8 years ago) | |
| US6355656 | SANDOZ | Phenidate drug formulations having diminished abuse potential |
Dec, 2015
(8 years ago) | |
| US5837284 | SANDOZ | Delivery of multiple doses of medications |
Dec, 2015
(8 years ago) | |
| US6528530 | SANDOZ | Phenidate drug formulations having diminished abuse potential |
Dec, 2015
(8 years ago) | |
| US6635284 | SANDOZ | Delivery of multiple doses of medications |
Dec, 2015
(8 years ago) | |
| US6228398 | SANDOZ | Multiparticulate modified release composition |
Nov, 2019
(4 years ago) | |
| US6730325 | SANDOZ | Multiparticulate modified release composition |
Nov, 2019
(4 years ago) | |
Focalin Xr is owned by Sandoz.
Focalin Xr contains Dexmethylphenidate Hydrochloride.
Focalin Xr has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Focalin Xr are:
- US7431944
- US5908850
- US6355656
- US5837284
- US6528530
- US6635284
- US6228398
- US6730325
Focalin Xr was authorised for market use on 26 May, 2005.
Focalin Xr is available in capsule, extended release;oral dosage forms.
Focalin Xr can be used as method of treating attention deficit disorder using oral administration of a bi-modal or pulsatile release composition, a method of treating disease amenable to treatment with a phenidate drug by once daily oral administration of an extended release dosage form, method of treating attention deficit disorder and/or attention deficit hyperactivity disorder.
The generics of Focalin Xr are possible to be released after 01 November, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-80) | Oct 17, 2011 |
| New Dosing Schedule(D-121) | Oct 23, 2012 |
Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 May, 2005
Treatment: Method of treating attention deficit disorder and/or attention deficit hyperactivity disorder; A method of treating disease amenable to treatment with a phenidate drug by once daily oral administratio...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
FOCALIN XR family patents
